Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAquis Exchange Regulatory News (AQX)

  • This share is currently suspended. It was suspended at a price of 725.00
  • There is currently no data for AQX

Director/PDMR Notification

8 Apr 2021 07:00

RNS Number : 7513U
Aquis Exchange PLC
08 April 2021
 

8 April 2021

Aquis Exchange PLC

("Aquis", the "Company" or the "Group")

 

Director/PDMR Notification

 

Aquis Exchange PLC (AQX.L), the exchange services group, has been notified that Alasdair Haynes, CEO of the Company, sold 160,000 ordinary shares of 10p each in the Company ("Ordinary Shares") on 7 April 2021 at a price of £6.50 per Ordinary Share. Part of the sale is a result of his divorce settlement agreed in July 2017. Following this, Alasdair Haynes now holds 1,331,551 Ordinary Shares in the Company, representing 4.9% of the Company's issued share capital.

 

This announcement contains inside information under UK MAR.

 

Enquiries:

 

Aquis Exchange PLC

Tel: +44 (0) 20 3597 6321

Alasdair Haynes, CEO

Jonathan Clelland, CFO and COO

Belinda Keheyan, Head of Marketing

+44 (0) 7768 078 110

Liberum Capital Limited (Nominated Adviser and Joint Broker)

Tel: +44 (0) 20 3100 2000

Clayton Bush

Chris Clarke

Edward Thomas

Kane Collings

Canaccord Genuity Limited (Joint Broker)

Tel: +44 (0) 20 7523 8000

Emma Gabriel (Corporate Broking)

Jeremy Grime (Specialist Sales)

Alma PR (Financial PR Adviser)

Tel: +44 (0)20 3405 0209

Susie Hudson

aquis@almapr.co.uk

Kieran Breheny

Faye Calow

 

Notes to editors:

Aquis Exchange PLC is an exchange services group, which operates pan-European cash equities trading businesses (Aquis Exchange), growth and regulated primary markets (Aquis Stock Exchange/AQSE) and develops/licenses exchange software to third parties (Aquis Technologies).

Aquis Exchange is authorised and regulated by the UK Financial Conduct Authority and France's Autorité des Marchés Financiers to operate Multilateral Trading Facility businesses in the UK and in EU27 respectively. Aquis operates a lit order book and does not allow aggressive non-client proprietary trading, which has resulted in lower toxicity and signalling risk on Aquis than other trading venues in Europe. According to independent studies, trades on Aquis are less likely to lead to price movement than on other lit markets. Aquis uses a subscription pricing model which works by charging users according to the message traffic they generate, rather than a percentage of the value of each stock that they trade.

Aquis Stock Exchange (AQSE) is a stock market providing primary and secondary markets for equity and debt products. It is authorised as a Recognised Investment Exchange, which allows it to operate a regulated listings venue. The AQSE Growth Market is divided into two segments 'Access' and 'Apex', with different levels of admission criteria. The Access market focuses on earlier stage growth companies, while Apex is the intended market for larger, more established businesses.

Aquis Technologies is the software and technology division of Aquis Exchange PLC. It creates and licenses cutting-edge, cost-effective matching engine and trade surveillance technology for banks, brokers, investment firms and exchanges.

Aquis Exchange PLC (AQX.L) is listed on the Alternative Investment Market of the LSE (AIM) market. For more information, please go to www.aquis.eu

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them:

1

Details of the person discharging managerial responsibilities/person closely associated

 

a)

Name

 

Alasdair Haynes

2

Reason for the notification

 

a)

Position/status

 

Chief Executive Officer

b)

Initial notification/ Amendment

 

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

Name

 

Aquis Exchange plc

b)

LEI

 

213800IXJSF5E1SIW150

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

Description of the financial instrument, type of instrument

Identification code

 

 

Ordinary shares of 10 pence each

 

ISIN: GB00BD5JNK30

b)

Nature of the transaction

 

Sale of shares

c)

Price(s) and volume(s)

 

 

Price(s)

Volume(s)

 

£6.50

 

160,000

 

 

d)

Aggregated information

-Aggregated volume

-Price

 

 

n/a - as above

e)

Date of the transaction

 

07/04/2021

f)

Place of the transaction 

London Stock Exchange

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHFLFLASIIDIIL
Date   Source Headline
4th Apr 20227:00 amRNSDirector/PDMR Dealing
1st Apr 20223:53 pmRNSTransfer of UBS MTF Business Activities Completed
30th Mar 20229:35 amRNSExercise of Share Options and Total Voting Rights
29th Mar 20227:10 amRNSFinal Results and Board Appointments
29th Mar 20227:00 amRNSAdmission to Trading on the AQSE Growth Market
16th Mar 20227:00 amRNSTransfer of UBS MTF business activities to Aquis
11th Mar 20227:00 amRNSIntention to Dual List on the AQSE
24th Feb 20227:00 amRNSNotice of Results
8th Feb 20227:00 amRNSAquis Technologies partners with Investre
26th Nov 20219:48 amRNSExercise of Share Options and Total Voting Rights
26th Nov 20217:00 amRNSAppointment of New Chair
25th Nov 20217:00 amRNSDirector/PDMR Notification
23rd Sep 20215:39 pmRNSExercise of Share Options, Director Dealing & TVR
23rd Sep 20217:00 amRNSInterim Results
17th Sep 20217:00 amRNSBoard Appointment
1st Sep 20217:00 amRNSNotice of Results
25th Aug 20217:00 amRNSAppointment of independent NED to AQSE Board
2nd Aug 20217:00 amRNSAquis Exchange achieves record market share
28th Jun 20214:21 pmRNSExercise of Share Options and Director Dealing
27th May 20217:00 amRNSAQSE expands research for its top-tier stocks
18th May 20217:00 amRNSDual quotations with the Frankfurt Stock Exchange
13th May 20217:00 amRNSNew Senior Management Appointments
30th Apr 20217:00 amRNSDirector/PDMR Notification & Issue of Options
27th Apr 202112:41 pmRNSResult of Annual General Meeting
8th Apr 20217:00 amRNSDirector/PDMR Notification
31st Mar 20214:51 pmRNSPublication of ARA and Notice of AGM
31st Mar 20217:00 amRNSFinal Results
26th Mar 20217:00 amRNSNotice of Results
24th Mar 20217:00 amRNSAquis Exchange and ShareSoc Retail Investor Survey
26th Feb 20217:00 amRNSTrading and Operational Update
5th Feb 202112:07 pmRNSAppointment of Joint Broker
4th Feb 20218:03 amRNSAquis Exchange recommences trading in Swiss shares
14th Dec 20207:00 amRNSAQSE rule changes & market segments now in effect
26th Nov 20207:00 amRNSDirector/PDMR Notification
23rd Nov 20207:00 amRNSAQSE launches Market Maker Incentive Scheme
20th Nov 20202:00 pmRNSAquis works with SGX & AWS on cloud deployment
19th Oct 20207:00 amRNSAppointment to the AQSE Board
12th Oct 20207:00 amRNSAppointment of Independent Non-executive Director
9th Sep 20207:00 amRNSInterim Results
27th Aug 20207:00 amRNSNotice of Results
17th Jun 20207:00 amRNSBoard Appointment
16th Jun 20207:00 amRNSHolding(s) in Company
15th Jun 20207:01 amRNSDirector/PDMR Notification
15th Jun 20207:00 amRNSIssue of Options and Director/PDMR Notification
19th May 20201:26 pmRNSResult of Annual General Meeting
24th Apr 20207:00 amRNSPublication of ARA and Notice of AGM
20th Apr 20207:00 amRNSIssue of Options and Director/PDMR Notification
16th Apr 20207:00 amRNSFinal results
15th Apr 20207:00 amRNSExercise of Share Options & Total Voting Rights
24th Mar 20207:00 amRNSUpdate to Results Announcement Date

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.